We are live on
!
Find out more
ProShare Advisors Portfolio holdings
AUM
$67.5B
1-Year Est. Return
28.09%
This Quarter
Est. Return
+3.37%
1 Year Est. Return
+28.09%
3 Year Est. Return
+88.43%
5 Year Est. Return
+118.21%
10 Year Est. Return
+464.8%
AUM
$37.4B
AUM Growth
-$234M
(-0.62%)
Cap. Flow
-$832M
Cap. Flow
% of AUM
-2.23%
Top 10 Holdings %
Top 10 Hldgs %
26.05%
Holding
2,051
New
47
Increased
483
Reduced
1,317
Closed
203
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Qualcomm
QCOM
|
+$240M |
| 2 |
Sysco
SYY
|
+$180M |
| 3 |
Synopsys
SNPS
|
+$83.9M |
| 4 |
C.H. Robinson
CHRW
|
+$42.1M |
| 5 |
United Bankshares
UBSI
|
+$38.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
3M
MMM
|
+$216M |
| 2 |
Apple
AAPL
|
+$189M |
| 3 |
Microsoft
MSFT
|
+$115M |
| 4 |
Meta Platforms (Facebook)
META
|
+$68.7M |
| 5 |
Broadcom
AVGO
|
+$65.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 31.13% |
| 2 | Consumer Staples | 11.3% |
| 3 | Industrials | 10.65% |
| 4 | Financials | 9.24% |
| 5 | Consumer Discretionary | 9.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
701
Neurocrine Biosciences
NBIX
$17.7B
| $1.51M | ﹤0.01% |
10,958
-871
| -7% | -$119K |
|
|
PARA
702
DELISTED
Paramount Global Class B
PARA
| $1.49M | ﹤0.01% |
143,818
-8,046
| -5% | -$94.2K |
|
|
PR
703
Permian Resources
PR
$17.9B
| $1.49M | ﹤0.01% |
92,367
-12,076
| -12% | -$200K |
|
704
Lattice Semiconductor
LSCC
$17.6B
| $1.48M | ﹤0.01% |
25,563
+2,080
| +9% | +$144K |
|
705
Cytokinetics
CYTK
$11B
| $1.44M | ﹤0.01% |
26,567
-2,600
| -9% | -$157K |
|
706
Central Garden & Pet Co
CENT
$2.74B
| $1.39M | ﹤0.01% |
36,208
-14,909
| -29% | -$623K |
|
707
Cirrus Logic
CRUS
$6.74B
| $1.39M | ﹤0.01% |
10,901
+519
| +5% | +$54.4K |
|
708
Fabrinet
FN
$17.1B
| $1.38M | ﹤0.01% |
5,656
-1,756
| -24% | -$372K |
|
|
CHX
709
DELISTED
ChampionX
CHX
| $1.38M | ﹤0.01% |
41,572
-2,957
| -7% | -$101K |
|
710
FTAI Aviation
FTAI
$22.2B
| $1.38M | ﹤0.01% |
13,342
-4,556
| -25% | -$362K |
|
711
Amkor Technology
AMKR
$16.1B
| $1.37M | ﹤0.01% |
34,300
-3,494
| -9% | -$116K |
|
|
ITCI
712
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $1.37M | ﹤0.01% |
19,965
-3,656
| -15% | -$254K |
|
713
BellRing Brands
BRBR
$1.51B
| $1.36M | ﹤0.01% |
23,834
-6,275
| -21% | -$359K |
|
714
Abercrombie & Fitch
ANF
$4.17B
| $1.35M | ﹤0.01% |
7,563
-2,317
| -23% | -$336K |
|
715
HealthEquity
HQY
$7.91B
| $1.34M | ﹤0.01% |
15,503
-3,974
| -20% | -$321K |
|
716
Commault Systems
CVLT
$5.89B
| $1.31M | ﹤0.01% |
10,763
-2,564
| -19% | -$275K |
|
|
ETRN
717
DELISTED
Equitrans Midstream Corporation Common Stock
ETRN
| $1.31M | ﹤0.01% |
100,736
-22,338
| -18% | -$300K |
|
718
Simpson Manufacturing
SSD
$7.98B
| $1.3M | ﹤0.01% |
7,742
-2,057
| -21% | -$360K |
|
|
BPMC
719
DELISTED
Blueprint Medicines
BPMC
| $1.29M | ﹤0.01% |
12,012
-3,206
| -21% | -$321K |
|
720
Synaptics
SYNA
$4.41B
| $1.29M | ﹤0.01% |
14,660
+5,511
| +60% | +$499K |
|
721
FMC
FMC
$1.42B
| $1.28M | ﹤0.01% |
22,214
+1,467
| +7% | +$87.7K |
|
722
Medpace
MEDP
$16.8B
| $1.26M | ﹤0.01% |
3,068
-269
| -8% | -$107K |
|
723
Matador Resources
MTDR
$6.31B
| $1.23M | ﹤0.01% |
20,660
-5,119
| -20% | -$321K |
|
724
Henry Schein
HSIC
$9.74B
| $1.21M | ﹤0.01% |
18,860
+1,165
| +7% | +$82K |
|
725
Generac Holdings
GNRC
$11.9B
| $1.21M | ﹤0.01% |
9,129
-1,940
| -18% | -$268K |
|
Similar funds
ProShare Advisors's Q2 2024 Portfolio in Review
As of Q2 2024, ProShare Advisors held 2,051 positions worth $37.4B, down 0.62% from $37.6B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
ProShare Advisors's Q2 2024 filing shows 47 new, 483 increased, 1,317 reduced and 203 closed positions. Its largest new stake was KKR & Co: 135,149 shares worth $14.2M. The largest sale was 3M, an estimated $216M.
By sector, the portfolio is most concentrated in Technology at 31% of assets, up from 29% a quarter earlier, followed by Consumer Staples and Industrials.
- ProShare Advisors's largest Q2 2024 buy was KKR & Co: 135,149 shares worth $14.2M.
- ProShare Advisors added most to Qualcomm in Q2 2024, an estimated $240M increase.
- ProShare Advisors's biggest Q2 2024 reduction was 3M, cutting an estimated $216M.
- ProShare Advisors fully exited Leggett & Platt in Q2 2024, selling an estimated $24.6M.
- ProShare Advisors's ten largest holdings make up 26% of its $37.4B portfolio in Q2 2024.
- ProShare Advisors opened 47 new positions and closed 203 in Q2 2024.
- ProShare Advisors's portfolio value fell 0.62% quarter-over-quarter to $37.4B.
Based on ProShare Advisors's 13F filing for Q2 2024, filed 13 Aug 2024.